Rebecca Auer

Title: Rebecca Auer: Innovator in Oncolytic Virus Research

Introduction

Rebecca Auer is a prominent inventor based in Ottawa, Canada. She has made significant contributions to the field of cancer treatment through her innovative research. Her work focuses on the development of oncolytic viruses, which are engineered to selectively target and destroy cancer cells.

Latest Patents

Rebecca Auer holds a patent for an oncolytic rhabdovirus expressing interleukin-12 (IL12). This patent discloses an oncolytic recombinant Maraba virus whose genome comprises nucleic acid sequences that encode an IL12 protein or a functional portion thereof. The patent also outlines a method for treating cancer in patients using this oncolytic recombinant Maraba virus. Additionally, it provides details on a tumor cell infected with the oncolytic rhabdovirus for use as an infected cell vaccine (ICV) in cancer treatment.

Career Highlights

Rebecca Auer has established herself as a leading figure in cancer research. Her innovative approach to utilizing oncolytic viruses has opened new avenues for cancer therapy. She is associated with Turnstone Limited Partnership, where she continues to advance her research and development efforts.

Collaborations

Rebecca collaborates with notable colleagues, including Almohanad Alkayyal and John Cameron Bell. These partnerships enhance her research capabilities and contribute to the advancement of oncolytic virus therapies.

Conclusion

Rebecca Auer's work in the field of oncolytic viruses represents a significant advancement in cancer treatment. Her innovative patent and collaborative efforts position her as a key player in the ongoing fight against cancer.